Till 4 PM today, the volume traded on NSE & BSE for Bajaj Finserv was -22.25% lower than the previous trading session. Volume traded is an important indicator along with price to study trends.

GSK has filed a pair of lawsuits against Moderna, claiming infringement of patents covering mRNA vaccines for COVID-19 and respiratory syncytial virus (RSV). According to court documents, the ...

GSK has revealed updated results from its phase 2b trial of its antisense drug for hepatitis B virus (HBV) infections, which reveal a sharp decline in the proportion of patients with undetectable ...

The Bajaj Finserv Flexi Cap Fund Regular Growth has an AUM of 3883.01 crores & has delivered CAGR of 0.00% in the last 5 years. The fund has an exit load of 1.00% and an expense ratio of 1.85%.

Bajaj Finserv Asset Management Limited manages assets worth ₹ 16,460.28 crores. It’s current offering of mutual fund schemes includes 4 equity, 2 debt and 2 hybrid schemes. What is the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together. The Company is ...

The proposed transaction is an all equity merger, under which on the Scheme becoming effective, 4.39 shares of the Company will be allotted for every share of GSK CH India.The acquisition is in ...

Bajaj Finserv is currently trading at Rs 1756.85, reflecting a gain of 1.23% today, while achieving a modest return of 0.27% over the past month. Bajaj Finserv has recently surpassed its 100-day ...